Skip to content Skip to footer
Subscribe Now
Ono & Reborna Biosciences 
NEWS

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

Shots:Ono Pharmaceutical entered into an option agreement to obtain exclusive rights for identified small-molecule compounds developed by leveraging Reborna’s proprietary RNA-targeting drug discovery platformFurthermore, the companies will collaborate to discover small molecule drug candidates for mutually selected rare neurological disordersUpon exercising the option, Ono will gain exclusive worldwide rights to develop, manufacture, and…
April 1, 2025

Read more

VIEWPOINTS_Meri Beckwith _2024
VIEWPOINTS

Infusing AI in Clinical Trials: Meri Beckwith from Lindus Health in Conversation with PharmaShots

Shots: Meri Beckwith, Co-Founder of Lindus Health engages in a striking conversation with PharmaShots Meri talks about bridging the gaps of clinical trials in CNS/Neurology by leveraging LLMs that are trained on nearly a million clinical trial protocols and simple machine learning models to monitor real-time clinical trial data Meri highlights the importance of multidisciplinary…
May 8, 2024

Read more

VIEWPOINTS_Dr. Samiah Al-Zaidy_2023
VIEWPOINTS

Dr. Samiah Al-Zaidy, VP of Clinical Development at Passage Bio Shares Insights on Additional Interim Data from the Imagine-1 Study for GM1 Gangliosidosis

Shots:Samiah Al-Zaidy spoke about the interim clinical data from Imagine-1, P-I/II trial of PBGM01 for GM1 gangliosidosis presented at the 19th Annual WORLDSymposium 2023She also talked about how the presentation at WORLDSymposium contributed to raising awareness about GM1 Gangliosidosis which is a rare and fatal diseaseThe interview showcases Passage Bio’s mission to…
May 22, 2023

Read more